Patents by Inventor Brenda L. Palucki

Brenda L. Palucki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperazine urea derivatives as melanocortin-4 receptor agonists
    Patent number: 7414057
    Abstract: Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: August 19, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Raman Kumar Bakshi, Ravi P. Nargund, Brenda L. Palucki, Min K. Park, Zhixiong Ye
  • Substituted piperidines as melanocortin receptor agonists
    Patent number: 6767915
    Abstract: Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: July 27, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Yingjie Lai, Ravi P. Nargund, Brenda L. Palucki, Min K. Park, Iyassu K. Sebhat, Zhixiong Ye, Arthur A. Patchett
  • SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS
    Publication number: 20030236262
    Abstract: Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: January 27, 2003
    Publication date: December 25, 2003
    Inventors: Raman K Bakshi, Khaled J Barakat, Yingjie Lai, Ravi P Nargund, Brenda L Palucki, Min K Park, Iyassu K Sebhat, Zhixiong Ye, Arthur A Patchett
  • Spiropiperidine derivatives as melanocortin receptor agonists
    Patent number: 6472398
    Abstract: Certain novel spiropiperidine derivatives of structural formula Ia wherein the substituents are as defined herein are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 29, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Brenda L. Palucki, Ravi P. Nargund
  • Substituted piperidines as melanocortin receptor agonists
    Patent number: 6458790
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment and control of obesity, diabetes, and sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 1, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Brenda L. Palucki, Khaled J. Barakat, Liangqin Guo, Yingjie Lai, Ravi P. Nargund, Min K. Park, Patrick G. Pollard, Iyassu K. Sebhat, Zhixiong Ye
  • Substituted piperidines as melanocortin-4 receptor agonists
    Publication number: 20020137664
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
    Type: Application
    Filed: November 21, 2001
    Publication date: September 26, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Ravi P. Nargund, Brenda L. Palucki, Arthur A. Patchett, Iyassu Sebhat, Zhixiong Ye, Leonardus H.T. Van Der Ploeg
  • Spiropiperidine derivatives as melanocortin receptor agonists
    Patent number: 6410548
    Abstract: Certain novel spiropiperidine compounds are agonists of melanocortin receptor(s) and are useful for the treatment, control or prevention of diseases and disorders responsive to the activation of melanocortin receptors. The compounds of the present invention are therefore useful for treatment of diseases and disorders such as obesity, diabetes, sexual dysfunction including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: June 25, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ravi P. Nargund, Zhixiong Ye, Brenda L. Palucki, Raman K. Bakshi, Arthur A. Patchett, Leonardus H. T. Van Der Ploeg
  • Substituted piperidines as melanocortin-4 receptor agonists
    Patent number: 6350760
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: February 26, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Ravi P. Nargund, Brenda L. Palucki, Arthur A. Patchett, Iyassu Sebhat, Zhixiong Ye, Leonardus H. T. Van Der Ploeg
  • Substituted piperidines as melanocortin receptor agonists
    Publication number: 20020019523
    Abstract: Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: March 20, 2001
    Publication date: February 14, 2002
    Inventors: Brenda L. Palucki, Khaled J. Barakat, Liangqin Guo, Yingjie Lai, Ravi P. Nargund, Min K. Park, Patrick G. Pollard, Iyassu K. Sebhat, Zhixiong Ye
  • Spiropiperidine derivatives as melanocortin receptor agonists
    Publication number: 20010029259
    Abstract: Certain novel spiropiperidine compounds are agonists of melanocortin receptor(s) and are useful for the treatment, control or prevention of diseases and disorders responsive to the activation of melanocortin receptors. The compounds of the present invention are therefore useful for treatment of diseases and disorders such as obesity, diabetes, sexual dysfunction including erectile dysfunction and female sexual dysfunction.
    Type: Application
    Filed: February 12, 2001
    Publication date: October 11, 2001
    Inventors: Ravi P. Nargund, Zhixiong Ye, Brenda L. Palucki, Raman K. Bakshi, Arthur A. Patchett, Leonardus H.T. Van Der Ploeg
  • Spiropiperidine derivatives as melanocortin receptor agonists
    Patent number: 6294534
    Abstract: Certain novel spiropiperidine compounds are agonists of melanocortin receptor(s) and are useful for the treatment, control or prevention of diseases and disorders responsive to the activation of melanocortin receptors. The compounds of the present invention are therefore useful for treatment of diseases and disorders such as obesity, diabetes, sexual dysfunction including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ravi P. Nargund, Brenda L. Palucki, Zhixiong Ye, Raman K. Bakshi, Arthur A. Patchett, Leonardus H. T. Van Der Ploeg